PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

Logo of curroncolLink to Publisher's site
 
From:
Published online 2017 February 27. doi: 10.3747/co.24.3586

TABLE II

Key adverse events

Adverse eventChemotherapy with ...

Rituximab (n=597)Obinutuzumab (n=595)
Any adverse event [n (%)]587 (98.3)592 (99.5)
Grade 3 or greater events [n (%)]a405 (67.8)444 (74.6)
  Neutropenia226 (37.9)261 (43.9)
  Leucopenia50 (8.4)51 (8.6)
  Febrile neutropenia29 (4.9)41 (6.9)
  Infusion-related reactions22 (3.7)40 (6.7)
  Thrombocytopenia16 (2.7)36 (6.1)
Grade 3 or greater events of special interest, by category [n (%)]
  Infections93 (15.6)119 (20.0)
  Infusion-related reactions40 (6.7)74 (12.4)
  Second neoplasms16 (2.7)28 (4.7)
Consequential adverse events [n (%)]
  Classified as serious238 (39.9)274 (46.1)
  Cause of treatment discontinuation85 (14.2)97 (16.3)
  Fatal20 (3.4)24 (4.0)
Change from baseline IgG level at end of induction (g/L)
  Median−1.46b−1.50c
  Range−16.4 to 9.1−22.3 to 6.5
aConstituting 5% or more in either arm.
bEvaluable: n=472.
cEvaluable: n=462.

IgG = immunoglobulin G.